Oltipraz therapy in patients with liver fibrosis or cirrhosis

A randomized, double-blind, placebo-controlled phase II trial

Sang Geon Kim, Young Mi Kim, Jong Young Choi, Joon Yeol Han, Jeong Won Jang, Se Hyun Cho, Soon-Ho Um, Chae Yoon Chon, Dong Hoo Lee, Ja June Jang, Eunsil Yu, Young Sok Lee

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objectives Oltipraz, a cancer chemopreventive agent, has an anticirrhotic effect in animals. A phase II trial was designed to investigate the preliminary efficacy of oltipraz therapy in liver fibrosis or cirrhosis. Methods Of 83 patients who were randomized to receive placebo, oltipraz 60 mg bid or oltipraz 90 mg qd for 24 weeks, 68 completed the study without any major protocol violation. Pre- and post-treatment liver biopsies, and blood fibrosis markers were assessed. Key findings Twenty-four weeks of oltipraz treatment showed no significant differences in the proportions of patients showing an improvement in histological outcomes, including Ishak fibrosis score. In the oltipraz 60 mg bid group, there was a trend of decreases in hepatic collagen area and plasma transforming growth factor-β1 (TGF-β1, a blood fibrosis marker) levels from baseline to week 24. In the per-protocol population (n = 68), decreases in plasma TGF-β1 correlated with those in the Ishak fibrosis score, suggesting that circulating TGF-β1 serves a possible indicator for fibrosis treatment. Conclusions No significant differences in liver histological outcomes were seen among the three treatment groups in this 24-week pilot study. Our finding indicates an association between TGF-β1 repression and improvement in the histological index of fibrosis.

Original languageEnglish
Pages (from-to)627-635
Number of pages9
JournalJournal of Pharmacy and Pharmacology
Volume63
Issue number5
DOIs
Publication statusPublished - 2011 May 1

Fingerprint

Liver Cirrhosis
Fibrosis
Placebos
Liver
Therapeutics
Transforming Growth Factors
oltipraz
Collagen
Biopsy
Population
Neoplasms

Keywords

  • clinical trial
  • liver fibrosis and cirrhosis
  • oltipraz
  • TGF-β1

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Oltipraz therapy in patients with liver fibrosis or cirrhosis : A randomized, double-blind, placebo-controlled phase II trial. / Kim, Sang Geon; Kim, Young Mi; Choi, Jong Young; Han, Joon Yeol; Jang, Jeong Won; Cho, Se Hyun; Um, Soon-Ho; Chon, Chae Yoon; Lee, Dong Hoo; Jang, Ja June; Yu, Eunsil; Lee, Young Sok.

In: Journal of Pharmacy and Pharmacology, Vol. 63, No. 5, 01.05.2011, p. 627-635.

Research output: Contribution to journalArticle

Kim, Sang Geon ; Kim, Young Mi ; Choi, Jong Young ; Han, Joon Yeol ; Jang, Jeong Won ; Cho, Se Hyun ; Um, Soon-Ho ; Chon, Chae Yoon ; Lee, Dong Hoo ; Jang, Ja June ; Yu, Eunsil ; Lee, Young Sok. / Oltipraz therapy in patients with liver fibrosis or cirrhosis : A randomized, double-blind, placebo-controlled phase II trial. In: Journal of Pharmacy and Pharmacology. 2011 ; Vol. 63, No. 5. pp. 627-635.
@article{dd874ee4ea6c4460bf7d9d931490796d,
title = "Oltipraz therapy in patients with liver fibrosis or cirrhosis: A randomized, double-blind, placebo-controlled phase II trial",
abstract = "Objectives Oltipraz, a cancer chemopreventive agent, has an anticirrhotic effect in animals. A phase II trial was designed to investigate the preliminary efficacy of oltipraz therapy in liver fibrosis or cirrhosis. Methods Of 83 patients who were randomized to receive placebo, oltipraz 60 mg bid or oltipraz 90 mg qd for 24 weeks, 68 completed the study without any major protocol violation. Pre- and post-treatment liver biopsies, and blood fibrosis markers were assessed. Key findings Twenty-four weeks of oltipraz treatment showed no significant differences in the proportions of patients showing an improvement in histological outcomes, including Ishak fibrosis score. In the oltipraz 60 mg bid group, there was a trend of decreases in hepatic collagen area and plasma transforming growth factor-β1 (TGF-β1, a blood fibrosis marker) levels from baseline to week 24. In the per-protocol population (n = 68), decreases in plasma TGF-β1 correlated with those in the Ishak fibrosis score, suggesting that circulating TGF-β1 serves a possible indicator for fibrosis treatment. Conclusions No significant differences in liver histological outcomes were seen among the three treatment groups in this 24-week pilot study. Our finding indicates an association between TGF-β1 repression and improvement in the histological index of fibrosis.",
keywords = "clinical trial, liver fibrosis and cirrhosis, oltipraz, TGF-β1",
author = "Kim, {Sang Geon} and Kim, {Young Mi} and Choi, {Jong Young} and Han, {Joon Yeol} and Jang, {Jeong Won} and Cho, {Se Hyun} and Soon-Ho Um and Chon, {Chae Yoon} and Lee, {Dong Hoo} and Jang, {Ja June} and Eunsil Yu and Lee, {Young Sok}",
year = "2011",
month = "5",
day = "1",
doi = "10.1111/j.2042-7158.2011.01259.x",
language = "English",
volume = "63",
pages = "627--635",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Pharmaceutical Press",
number = "5",

}

TY - JOUR

T1 - Oltipraz therapy in patients with liver fibrosis or cirrhosis

T2 - A randomized, double-blind, placebo-controlled phase II trial

AU - Kim, Sang Geon

AU - Kim, Young Mi

AU - Choi, Jong Young

AU - Han, Joon Yeol

AU - Jang, Jeong Won

AU - Cho, Se Hyun

AU - Um, Soon-Ho

AU - Chon, Chae Yoon

AU - Lee, Dong Hoo

AU - Jang, Ja June

AU - Yu, Eunsil

AU - Lee, Young Sok

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Objectives Oltipraz, a cancer chemopreventive agent, has an anticirrhotic effect in animals. A phase II trial was designed to investigate the preliminary efficacy of oltipraz therapy in liver fibrosis or cirrhosis. Methods Of 83 patients who were randomized to receive placebo, oltipraz 60 mg bid or oltipraz 90 mg qd for 24 weeks, 68 completed the study without any major protocol violation. Pre- and post-treatment liver biopsies, and blood fibrosis markers were assessed. Key findings Twenty-four weeks of oltipraz treatment showed no significant differences in the proportions of patients showing an improvement in histological outcomes, including Ishak fibrosis score. In the oltipraz 60 mg bid group, there was a trend of decreases in hepatic collagen area and plasma transforming growth factor-β1 (TGF-β1, a blood fibrosis marker) levels from baseline to week 24. In the per-protocol population (n = 68), decreases in plasma TGF-β1 correlated with those in the Ishak fibrosis score, suggesting that circulating TGF-β1 serves a possible indicator for fibrosis treatment. Conclusions No significant differences in liver histological outcomes were seen among the three treatment groups in this 24-week pilot study. Our finding indicates an association between TGF-β1 repression and improvement in the histological index of fibrosis.

AB - Objectives Oltipraz, a cancer chemopreventive agent, has an anticirrhotic effect in animals. A phase II trial was designed to investigate the preliminary efficacy of oltipraz therapy in liver fibrosis or cirrhosis. Methods Of 83 patients who were randomized to receive placebo, oltipraz 60 mg bid or oltipraz 90 mg qd for 24 weeks, 68 completed the study without any major protocol violation. Pre- and post-treatment liver biopsies, and blood fibrosis markers were assessed. Key findings Twenty-four weeks of oltipraz treatment showed no significant differences in the proportions of patients showing an improvement in histological outcomes, including Ishak fibrosis score. In the oltipraz 60 mg bid group, there was a trend of decreases in hepatic collagen area and plasma transforming growth factor-β1 (TGF-β1, a blood fibrosis marker) levels from baseline to week 24. In the per-protocol population (n = 68), decreases in plasma TGF-β1 correlated with those in the Ishak fibrosis score, suggesting that circulating TGF-β1 serves a possible indicator for fibrosis treatment. Conclusions No significant differences in liver histological outcomes were seen among the three treatment groups in this 24-week pilot study. Our finding indicates an association between TGF-β1 repression and improvement in the histological index of fibrosis.

KW - clinical trial

KW - liver fibrosis and cirrhosis

KW - oltipraz

KW - TGF-β1

UR - http://www.scopus.com/inward/record.url?scp=79954780467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954780467&partnerID=8YFLogxK

U2 - 10.1111/j.2042-7158.2011.01259.x

DO - 10.1111/j.2042-7158.2011.01259.x

M3 - Article

VL - 63

SP - 627

EP - 635

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 5

ER -